FDA panel backs Herceptin and Avastin biosimilars.
Watson for Genomics produces treatment insights for glioblastoma in 10 minutes.
Report raises concerns about outcome of MYSTIC trial.
Panel unanimously back CTL019
EU inspectors require re-inspection of Bangalore plant.
Gradient Ventures will foster AI-focused startups, including those in healthcare.
Regulator drops demand for further phase 3 trial.
Mylotarg backed by advisers after withdrawal in 2010.